Skip to Main Content
Table 6—

Therapies proven effective in diabetes prevention trials

Study (ref.)nPopulationMean age (years)Duration (years)Intervention (daily dose)Conversion in control subjects (%/year)Relative risk
Lifestyle        
    Finnish DPS (11) 522 IGT, BMI ≥25 kg/m2 55 3.2 Individual diet/exercise 0.42 (0.30–0.70) 
    DPP (10) 2,161* IGT, BMI ≥24 kg/m2, FPG >5.3 mmol/l 51 Individual diet/exercise 10 0.42 (0.34–0.52) 
    Da Qing (12) 259* IGT (randomized groups) 45 Group diet/exercise 16 0.62 (0.44–0.86) 
    Toranomon study (28) 458 IGT (men), BMI = 24 kg/m2 55 Individual diet/exercise 0.33 (0.10–1.0) 
    Indian DPP (16) 269* IGT 46 2.5 Individual diet/exercise 22 0.71 (0.63–0.79) 
Medications        
    DPP (10) 2,155* IGT, BMI >24 kg/m2, FPG >5.3 mmol/l 51 2.8 Metformin (1,700 mg) 10 0.69 (0.57–0.83) 
    Indian DPP (16) 269* IGT 46 2.5 Metformin (500 mg) 22 0.74 (0.65–0.81) 
    STOP NIDDM (14) 1,419 IGT, FPG >5.6 mmol/l 54 3.2 Acarbose (300 mg) 13 0.75 (0.63–0.90) 
    XENDOS (29) 3,277 BMI >30 kg/m2 43 Orlistat (360 mg) 0.63 (0.46–0.86) 
    DREAM (15) 5,269 IGT or IFG 55 3.0 Rosiglitazone (8 mg) 0.40 (0.35–0.46) 
Study (ref.)nPopulationMean age (years)Duration (years)Intervention (daily dose)Conversion in control subjects (%/year)Relative risk
Lifestyle        
    Finnish DPS (11) 522 IGT, BMI ≥25 kg/m2 55 3.2 Individual diet/exercise 0.42 (0.30–0.70) 
    DPP (10) 2,161* IGT, BMI ≥24 kg/m2, FPG >5.3 mmol/l 51 Individual diet/exercise 10 0.42 (0.34–0.52) 
    Da Qing (12) 259* IGT (randomized groups) 45 Group diet/exercise 16 0.62 (0.44–0.86) 
    Toranomon study (28) 458 IGT (men), BMI = 24 kg/m2 55 Individual diet/exercise 0.33 (0.10–1.0) 
    Indian DPP (16) 269* IGT 46 2.5 Individual diet/exercise 22 0.71 (0.63–0.79) 
Medications        
    DPP (10) 2,155* IGT, BMI >24 kg/m2, FPG >5.3 mmol/l 51 2.8 Metformin (1,700 mg) 10 0.69 (0.57–0.83) 
    Indian DPP (16) 269* IGT 46 2.5 Metformin (500 mg) 22 0.74 (0.65–0.81) 
    STOP NIDDM (14) 1,419 IGT, FPG >5.6 mmol/l 54 3.2 Acarbose (300 mg) 13 0.75 (0.63–0.90) 
    XENDOS (29) 3,277 BMI >30 kg/m2 43 Orlistat (360 mg) 0.63 (0.46–0.86) 
    DREAM (15) 5,269 IGT or IFG 55 3.0 Rosiglitazone (8 mg) 0.40 (0.35–0.46) 
*

Number of participants in the indicated comparisons, not necessarily in the entire study.

Calculated from information in the article. DPP, Diabetes Prevention Program; DREAM, Diabetes REduction Assessment with ramipril and rosiglitazone Medication; DPS, Diabetes Prevention Study; STOP NIDDM, Study to Prevent Non-Insulin Dependent Diabetes; XENDOS, Xenical in the prevention of Diabetes in Obese Subjects. This table has been reprinted with permission (30) with some modification.

Close Modal

or Create an Account

Close Modal
Close Modal